1. Home
  2. SWBI vs ANL Comparison

SWBI vs ANL Comparison

Compare SWBI & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Smith & Wesson Brands Inc.

SWBI

Smith & Wesson Brands Inc.

HOLD

Current Price

$15.21

Market Cap

688.3M

Sector

Industrials

ML Signal

HOLD

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$11.80

Market Cap

731.6M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SWBI
ANL
Founded
1852
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Ordnance And Accessories
Sector
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
688.3M
731.6M
IPO Year
2000
2022

Fundamental Metrics

Financial Performance
Metric
SWBI
ANL
Price
$15.21
$11.80
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$14.00
$20.00
AVG Volume (30 Days)
386.4K
289.2K
Earning Date
06-17-2026
04-10-2026
Dividend Yield
3.37%
N/A
EPS Growth
N/A
N/A
EPS
0.05
N/A
Revenue
$474,661,000.00
N/A
Revenue This Year
$7.61
$36.02
Revenue Next Year
$3.72
N/A
P/E Ratio
$309.90
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.73
$0.88
52 Week High
$15.79
$17.25

Technical Indicators

Market Signals
Indicator
SWBI
ANL
Relative Strength Index (RSI) 54.53 46.83
Support Level $13.90 $11.86
Resistance Level $15.24 $15.63
Average True Range (ATR) 0.42 1.36
MACD 0.01 -0.36
Stochastic Oscillator 68.48 33.40

Price Performance

Historical Comparison
SWBI
ANL

About SWBI Smith & Wesson Brands Inc.

Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

Share on Social Networks: